Pipeline

Program
Modality
Indication
Preclinical
Early
Clinical
Late
Clinical
Rights
Pipeline

A GPRC5D and BCMA Bispecific CAR-T Product Demonstrated Dual Antigen Targeting Capability and Efficacy Against Multiple Myeloma Cells Bearing BCMA Mutations Associated with Treatment Resistance

Chang et al. November 26, 2024

G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and B-Cell Maturation Antigen (BCMA) Bi-Specific Dual Chimeric Antigen Receptors (CARs) Effectively Address Antigen Escape and Tumor Heterogeneity Challenge in Multiple Myeloma (MM)

Chang et al., American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting May 11, 2024

Development of a Novel Allogeneic γδ-T Platform for Off-the-Shelf Adoptive Cell Therapy for Oncology and Autoimmune Diseases

Nanbakhsh et al., American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting May 10, 2024

A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Study ID: NCT06644118 Status: Active

For more information, please contact clinical.trial@overlandtx.com.